SciClone Pharmaceuticals (Holdings) Limited

SEHK:6600 Stock Report

Market Cap: HK$11.4b

SciClone Pharmaceuticals (Holdings) Dividend

Dividend criteria checks 0/6

SciClone Pharmaceuticals (Holdings) does not currently pay a dividend.

Key information

0%

Dividend yield

0%

Payout ratio

Industry average yield3.7%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per shareHK$1.85
Dividend yield forecast in 3Y2.5%

Recent dividend updates

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

May 31
SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

Recent updates

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Apr 02
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Dec 14
Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Jun 19
Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

May 31
SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Feb 17
Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Dec 02
Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Oct 04
We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Jul 27
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Jun 02
An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if 6600's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6600's dividend payments have been increasing.


Dividend Yield vs Market

SciClone Pharmaceuticals (Holdings) Dividend Yield vs Market
How does 6600 dividend yield compare to the market?
SegmentDividend Yield
Company (6600)0%
Market Bottom 25% (HK)3.4%
Market Top 25% (HK)8.0%
Industry Average (Pharmaceuticals)3.7%
Analyst forecast in 3 Years (6600)2.5%

Notable Dividend: Unable to evaluate 6600's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6600's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: 6600 is not paying a notable dividend for the Hong Kong market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6600 has not reported any payouts.


Discover strong dividend paying companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.